Safety and efficacy of a novel miniaturized robotic assisted surgery system in hysterectomy: a prospective, investigational device exemption clinical trial.
Ricardo Estape, Piet Hinoul, Greg Heidrick et al.
✦ AI-curated · Sources linked
In 30 seconds
This prospective, multicentre, non-randomised Investigational Device Exemption trial assessed the safety and effectiveness of the MIRA miniaturized robotic system for benign hysterectomy. Five surgeons at three types of institutions operated on 35 consecutively enrolled patients. One procedure was converted to laparoscopy because of a technical malfunction. Ten adverse events were reported—two intraoperative device-related and eight postoperative procedure-related—and all resolved; none was Grade III or higher. The investigators concluded that the system was technically feasible with an acceptable short-term safety profile in this selected cohort.
Key findings
- One of 35 procedures required conversion to laparoscopy because of a technical malfunction.
- Ten adverse events occurred: two intraoperative device-related and eight postoperative procedure-related; all resolved, with no Grade III or higher events.
- Mean procedure duration was 141.8 min (median 127; range 73-273).
- Mean estimated blood loss was 52.6 ml (median 50 ml; range 10-200 ml).
Why it matters
Miniaturized robotic platforms may offer another technical approach to hysterectomy, but feasibility and safety findings from an early device trial need to be interpreted in the context of its selected cohort and short-term assessment. Reporting conversions, adverse events, operative duration and blood loss helps clinicians understand the outcomes evaluated before broader evidence is available.
What to keep in mind
The trial was non-randomised and included only 35 patients; the authors call for evaluation in larger, more diverse cohorts and with longer follow-up.